NYSE:CPHI China Pharma (CPHI) Stock Price, News & Analysis $1.50 -0.06 (-4.06%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$1.54 +0.04 (+2.57%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About China Pharma Stock (NYSE:CPHI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get China Pharma alerts:Sign Up Key Stats Today's Range$1.47▼$1.9050-Day Range$1.50▼$29.4952-Week Range$1.20▼$4.10Volume494,217 shsAverage Volume62,628 shsMarket Capitalization$48.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChina Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Read More… Receive CPHI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CPHI Stock News HeadlinesStockNews.com Begins Coverage on China Pharma (NYSE:CPHI)April 17 at 3:33 AM | americanbankingnews.comChina Pharma Stock Scheduled to Reverse Split on Tuesday, April 15th (NYSE:CPHI)April 11, 2025 | americanbankingnews.com🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining stocks like most gold analyst CFAs, I decided to visit every significant gold mine I could. 10+ site visits later, I've confirmed my theory... That the most profitable mines share three specific characteristics. When you find all three together, the returns can be staggering.April 18, 2025 | Golden Portfolio (Ad)China Pharma (NYSE:CPHI) Shares to Reverse Split on Tuesday, April 15thApril 11, 2025 | americanbankingnews.comChina Pharma Stock to Reverse Split on Tuesday, April 15th (NYSE:CPHI)April 11, 2025 | americanbankingnews.comChina Pharma (NYSE:CPHI) Earns Hold Rating from Analysts at StockNews.comApril 8, 2025 | americanbankingnews.comChina Pharma announces 1-for-10 reverse stock splitApril 5, 2025 | markets.businessinsider.comThe US relies on China for key medicines. They won’t be spared from tariffsFebruary 9, 2025 | msn.comSee More Headlines CPHI Stock Analysis - Frequently Asked Questions How have CPHI shares performed this year? China Pharma's stock was trading at $23.00 at the beginning of the year. Since then, CPHI stock has decreased by 93.5% and is now trading at $1.4966. View the best growth stocks for 2025 here. How were China Pharma's earnings last quarter? China Pharma Holdings, Inc. (NYSE:CPHI) announced its earnings results on Wednesday, August, 15th. The company reported ($100.00) earnings per share (EPS) for the quarter. The business earned $3.17 million during the quarter. China Pharma had a negative net margin of 85.56% and a negative trailing twelve-month return on equity of 63.93%. When did China Pharma's stock split? Shares of China Pharma reverse split before market open on Tuesday, April 15th 2025. The 1-10 reverse split was announced on Friday, April 4th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of China Pharma? Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of China Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that China Pharma investors own include iBio (IBIO), Biocept (BIOC), Micron Technology (MU), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP) and Bionano Genomics (BNGO). Company Calendar Last Earnings8/15/2018Today4/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:CPHI CIK1106644 Webwww.chinapharmaholdings.com Phone8689866811730Fax86-898-6681-9024Employees250Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,080,000.00 Net Margins-85.56% Pretax Margin-85.56% Return on Equity-63.93% Return on Assets-31.42% Debt Debt-to-Equity Ratio0.22 Current Ratio0.79 Quick Ratio0.26 Sales & Book Value Annual Sales$4.53 million Price / Sales10.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book2.14Miscellaneous Outstanding Shares32,619,000Free Float15,918,000Market Cap$48.82 million OptionableNot Optionable Beta0.77 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NYSE:CPHI) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.